- Home
- DTF vs NTRB Comparison
DTF vs NTRB Comparison
Compare DTF & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | NTRB |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 71.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DTF | NTRB |
|---|---|---|
| Price | $11.34 | $4.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 21.1K | 19.6K |
| Earning Date | 01-01-0001 | 12-11-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $10.29 | $3.72 |
| 52 Week High | $11.19 | $11.78 |
Technical Indicators
Market Signals| Indicator | DTF | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 45.40 |
| Support Level | $11.33 | $4.34 |
| Resistance Level | $11.40 | $4.77 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 33.36 | 38.63 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.